IPO Boutique

CinCor Pharma, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on CinCor Pharma, Inc. , and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
CinCor Pharma, Inc. CINC -
NASDAQ
$15.00-$17.00 $16.00 $21.0012.1 million 1/7/2022
Morgan Stanley, Jefferies, Evercore ISI
Co-Manager(s):
Oppenheimer
Health Care
Filing(s):

Filed 2021-12-17
Terms Added 2022-01-03



CinCor Pharma, Inc. Quote & Chart - Click for current quote - CINC

About CinCor Pharma, Inc. (adapted from CinCor Pharma, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "CINC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved